J. Alexander Bodkin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Monoamine Oxidase Inhibitors | 6 | 2022 | 154 | 1.030 |
Why?
|
| Selegiline | 6 | 2012 | 32 | 0.990 |
Why?
|
| Psychotropic Drugs | 2 | 2020 | 888 | 0.910 |
Why?
|
| Affective Disorders, Psychotic | 2 | 2019 | 187 | 0.730 |
Why?
|
| Antidepressive Agents | 10 | 2022 | 2913 | 0.700 |
Why?
|
| Glycine Dehydrogenase (Decarboxylating) | 1 | 2019 | 15 | 0.660 |
Why?
|
| Glycine Agents | 1 | 2019 | 16 | 0.660 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2020 | 348 | 0.580 |
Why?
|
| Depressive Disorder, Major | 8 | 2019 | 4816 | 0.530 |
Why?
|
| Job Satisfaction | 1 | 2020 | 549 | 0.530 |
Why?
|
| Glycine | 1 | 2019 | 672 | 0.500 |
Why?
|
| Psychiatry | 4 | 2020 | 1714 | 0.480 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 905 | 0.440 |
Why?
|
| Managed Care Programs | 1 | 2019 | 941 | 0.440 |
Why?
|
| Psychotic Disorders | 7 | 2019 | 3278 | 0.440 |
Why?
|
| Famous Persons | 1 | 2012 | 109 | 0.370 |
Why?
|
| Thiophenes | 2 | 2011 | 570 | 0.330 |
Why?
|
| Buprenorphine | 4 | 2019 | 661 | 0.330 |
Why?
|
| Anxiety Disorders | 5 | 2011 | 2754 | 0.310 |
Why?
|
| Amino Sugars | 1 | 2008 | 39 | 0.310 |
Why?
|
| Mental Health Services | 1 | 2019 | 1732 | 0.290 |
Why?
|
| Gift Giving | 1 | 2007 | 76 | 0.270 |
Why?
|
| Naltrexone | 2 | 2019 | 319 | 0.240 |
Why?
|
| Schizophrenia | 7 | 2017 | 6986 | 0.230 |
Why?
|
| Social Class | 1 | 2012 | 2000 | 0.210 |
Why?
|
| Phenelzine | 1 | 2022 | 28 | 0.210 |
Why?
|
| Tranylcypromine | 1 | 2022 | 30 | 0.210 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 3837 | 0.200 |
Why?
|
| Double-Blind Method | 8 | 2019 | 12450 | 0.190 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 2179 | 0.190 |
Why?
|
| Life Change Events | 1 | 2006 | 964 | 0.190 |
Why?
|
| Fees, Pharmaceutical | 1 | 2020 | 66 | 0.180 |
Why?
|
| Insurance, Psychiatric | 1 | 2020 | 66 | 0.180 |
Why?
|
| Drug Therapy, Combination | 5 | 2019 | 6320 | 0.160 |
Why?
|
| Depressive Disorder | 4 | 2012 | 3738 | 0.160 |
Why?
|
| Antipsychotic Agents | 2 | 2005 | 3077 | 0.150 |
Why?
|
| Patient Dropouts | 2 | 2012 | 411 | 0.140 |
Why?
|
| Videotape Recording | 1 | 1998 | 336 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2019 | 6035 | 0.130 |
Why?
|
| Biological Psychiatry | 1 | 1995 | 27 | 0.130 |
Why?
|
| Adult | 25 | 2020 | 223542 | 0.130 |
Why?
|
| Ambulatory Care | 2 | 2005 | 2780 | 0.130 |
Why?
|
| Administration, Cutaneous | 3 | 2012 | 716 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 2238 | 0.120 |
Why?
|
| Endophenotypes | 1 | 2017 | 258 | 0.120 |
Why?
|
| Bupropion | 1 | 1997 | 304 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2019 | 1765 | 0.120 |
Why?
|
| Random Allocation | 1 | 2019 | 2399 | 0.120 |
Why?
|
| Secondary Prevention | 3 | 2011 | 1479 | 0.110 |
Why?
|
| Thinking | 1 | 2017 | 320 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 3267 | 0.110 |
Why?
|
| Mental Disorders | 2 | 2012 | 6879 | 0.110 |
Why?
|
| Psychoanalytic Therapy | 2 | 2007 | 228 | 0.100 |
Why?
|
| Male | 29 | 2020 | 364781 | 0.100 |
Why?
|
| Tyramine | 1 | 2012 | 55 | 0.100 |
Why?
|
| Clonazepam | 2 | 1990 | 135 | 0.100 |
Why?
|
| Food-Drug Interactions | 1 | 2012 | 24 | 0.100 |
Why?
|
| Craniofacial Abnormalities | 1 | 2015 | 320 | 0.100 |
Why?
|
| Female | 26 | 2020 | 396943 | 0.090 |
Why?
|
| Dissent and Disputes | 1 | 2012 | 150 | 0.090 |
Why?
|
| Hospitals, Psychiatric | 1 | 2012 | 318 | 0.090 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2006 | 4636 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 2046 | 0.090 |
Why?
|
| Visual Perception | 1 | 1998 | 1406 | 0.090 |
Why?
|
| Middle Aged | 21 | 2020 | 223418 | 0.080 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2006 | 1994 | 0.080 |
Why?
|
| Panic | 1 | 1989 | 103 | 0.080 |
Why?
|
| Fetal Development | 1 | 2015 | 771 | 0.080 |
Why?
|
| Schizophrenic Psychology | 4 | 2009 | 1652 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2012 | 2696 | 0.080 |
Why?
|
| Bipolar Disorder | 2 | 2017 | 5124 | 0.080 |
Why?
|
| Humans | 34 | 2022 | 768451 | 0.080 |
Why?
|
| Hydroxylation | 1 | 2008 | 139 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2019 | 65409 | 0.070 |
Why?
|
| Placebos | 2 | 2005 | 1668 | 0.070 |
Why?
|
| Sertraline | 2 | 2000 | 209 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2020 | 2391 | 0.070 |
Why?
|
| Anti-Anxiety Agents | 1 | 1990 | 405 | 0.070 |
Why?
|
| Panic Disorder | 2 | 2004 | 613 | 0.070 |
Why?
|
| Symbolism | 1 | 2007 | 34 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2008 | 612 | 0.070 |
Why?
|
| Ethics Committees | 1 | 2007 | 51 | 0.070 |
Why?
|
| Esters | 1 | 2008 | 212 | 0.070 |
Why?
|
| Logistic Models | 2 | 2020 | 13324 | 0.070 |
Why?
|
| Trichosporon | 1 | 2006 | 9 | 0.070 |
Why?
|
| Molecular Conformation | 1 | 2008 | 542 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 12096 | 0.070 |
Why?
|
| Medicaid | 1 | 2020 | 2843 | 0.070 |
Why?
|
| Patient Care Planning | 1 | 2012 | 904 | 0.070 |
Why?
|
| Psychotherapy | 1 | 1995 | 1656 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 937 | 0.070 |
Why?
|
| Massachusetts | 1 | 2019 | 8908 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2012 | 2656 | 0.060 |
Why?
|
| Candida | 1 | 2006 | 172 | 0.060 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 1514 | 0.060 |
Why?
|
| Family Health | 1 | 2009 | 1256 | 0.060 |
Why?
|
| Drug Interactions | 3 | 2022 | 1421 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2008 | 1775 | 0.060 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2006 | 510 | 0.060 |
Why?
|
| Time Factors | 3 | 2019 | 40271 | 0.050 |
Why?
|
| Hypochondriasis | 1 | 2004 | 93 | 0.050 |
Why?
|
| Candida albicans | 1 | 2006 | 376 | 0.050 |
Why?
|
| Professional-Family Relations | 1 | 2007 | 501 | 0.050 |
Why?
|
| United States | 4 | 2020 | 73121 | 0.050 |
Why?
|
| Aged | 9 | 2020 | 171520 | 0.050 |
Why?
|
| Asperger Syndrome | 1 | 2002 | 57 | 0.050 |
Why?
|
| Conflict of Interest | 1 | 2007 | 556 | 0.050 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2002 | 1509 | 0.050 |
Why?
|
| Ethics, Medical | 1 | 2007 | 785 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2006 | 761 | 0.050 |
Why?
|
| Alcoholism | 1 | 2012 | 1993 | 0.050 |
Why?
|
| Comorbidity | 2 | 2015 | 10601 | 0.050 |
Why?
|
| Ligands | 1 | 2008 | 3281 | 0.050 |
Why?
|
| Cognition | 1 | 1998 | 7066 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2012 | 2526 | 0.050 |
Why?
|
| Fear | 1 | 1989 | 1494 | 0.040 |
Why?
|
| Fluoxetine | 2 | 1997 | 735 | 0.040 |
Why?
|
| Personality Inventory | 1 | 2002 | 1019 | 0.040 |
Why?
|
| Psychoanalytic Interpretation | 1 | 1998 | 55 | 0.040 |
Why?
|
| Repression, Psychology | 1 | 1998 | 46 | 0.040 |
Why?
|
| Adolescent | 4 | 2016 | 89168 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2008 | 5443 | 0.040 |
Why?
|
| 1-Naphthylamine | 1 | 1997 | 48 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1997 | 78 | 0.040 |
Why?
|
| Dysthymic Disorder | 1 | 1997 | 75 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2005 | 4041 | 0.030 |
Why?
|
| Dissociative Disorders | 1 | 1999 | 236 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2012 | 4538 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2006 | 6537 | 0.030 |
Why?
|
| Basal Ganglia Diseases | 1 | 1996 | 145 | 0.030 |
Why?
|
| Attitude of Health Personnel | 3 | 2002 | 3922 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 4453 | 0.030 |
Why?
|
| Certification | 1 | 1999 | 419 | 0.030 |
Why?
|
| Family | 2 | 2017 | 3208 | 0.030 |
Why?
|
| Personality Assessment | 2 | 2009 | 649 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 60045 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 15460 | 0.030 |
Why?
|
| Hypertension | 1 | 2012 | 8611 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1999 | 1539 | 0.020 |
Why?
|
| Meperidine | 1 | 1991 | 38 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 1995 | 648 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 1997 | 4861 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2016 | 590 | 0.020 |
Why?
|
| Anthropometry | 1 | 2015 | 1343 | 0.020 |
Why?
|
| Alprazolam | 1 | 1990 | 103 | 0.020 |
Why?
|
| Trazodone | 1 | 1990 | 67 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1998 | 2030 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2016 | 2079 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2012 | 335 | 0.020 |
Why?
|
| Child Abuse | 1 | 1998 | 1092 | 0.020 |
Why?
|
| Dopamine | 1 | 1996 | 1616 | 0.020 |
Why?
|
| Lorazepam | 1 | 1989 | 155 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 495 | 0.020 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1990 | 433 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 1990 | 307 | 0.020 |
Why?
|
| Catatonia | 1 | 1990 | 181 | 0.020 |
Why?
|
| Indicator Dilution Techniques | 1 | 2006 | 43 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 169418 | 0.020 |
Why?
|
| Echinocandins | 1 | 2006 | 53 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2006 | 71 | 0.020 |
Why?
|
| Amphotericin B | 1 | 2006 | 143 | 0.020 |
Why?
|
| Personality | 1 | 2009 | 558 | 0.020 |
Why?
|
| Self-Injurious Behavior | 1 | 2012 | 571 | 0.020 |
Why?
|
| Health Status | 1 | 1998 | 4096 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2006 | 393 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 8051 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1996 | 8730 | 0.010 |
Why?
|
| Erotica | 1 | 2002 | 28 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 10647 | 0.010 |
Why?
|
| Epilepsy | 1 | 1997 | 3324 | 0.010 |
Why?
|
| Triazoles | 1 | 2006 | 905 | 0.010 |
Why?
|
| Outpatients | 1 | 2009 | 1607 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6242 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 1965 | 0.010 |
Why?
|
| Age Factors | 1 | 1995 | 18478 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 6348 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1996 | 15965 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1999 | 617 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2362 | 0.010 |
Why?
|
| Specialty Boards | 1 | 1999 | 236 | 0.010 |
Why?
|
| Amnesia | 1 | 1999 | 258 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 10784 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 1991 | 2891 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2006 | 3050 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 6217 | 0.010 |
Why?
|
| Cues | 1 | 1998 | 884 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 14766 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 16712 | 0.010 |
Why?
|
| Child | 2 | 1998 | 80863 | 0.000 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2002 | 3742 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 10358 | 0.000 |
Why?
|
| Clinical Competence | 1 | 2002 | 4841 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1998 | 3629 | 0.000 |
Why?
|
| Depression | 1 | 2002 | 8235 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 39430 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 20231 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1998 | 42623 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1998 | 54914 | 0.000 |
Why?
|